Mark R. Flory strives to effectively leverage proteomic technologies to facilitate research efforts focused on identifying critical biomarkers and targets for multiple cancer indications. He received his Ph.D. in Molecular and Cellular Biology at the University of Washington and subsequently enjoyed postdoctoral training in biological mass spectrometry as a member of Ruedi Aebersold’s group at the Seattle Institute for Systems Biology. Mark has undertaken multiple positions in both industry and academic settings and is currently a Senior Scientist at Oregon Health and Science University (OHSU), specifically in CEDAR (Cancer Early Detection Advanced Research) Center at the OHSU Knight Cancer Institute. His research keywords include proteomics, mass spectrometry, biomarker, target, and cellular biology.
Mark R. Flory strives to effectively leverage proteomic technologies to facilitate research efforts focused on identifying critical biomarkers and targets for multiple cancer indications. He received his Ph.D. in Molecular and Cellular Biology at the University of Washington and subsequently enjoyed postdoctoral training in biological mass spectrometry as a member of Ruedi Aebersold’s group at the Seattle Institute for Systems Biology. Mark has undertaken multiple positions in both industry and academic settings and is currently a Senior Scientist at Oregon Health and Science University (OHSU), specifically in CEDAR (Cancer Early Detection Advanced Research) Center at the OHSU Knight Cancer Institute. His research keywords include proteomics, mass spectrometry, biomarker, target, and cellular biology.